MedTrace Logo

FTIH Study of ECC0509 in Healthy Volunteers

NCT05012423 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-09-25

No results posted yet for this study

Summary

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Conditions

Interventions

DRUG

Placebo

Matching Placebo will be administered as oral capsules.

DRUG

ECC0509

ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

DRUG

Placebo

Matching Placebo will be given orally during each dosing day.

DRUG

ECC0509

ECC0509 1 mg and 10 mg capsules

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2023-07-22
Completion
2023-07-22

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05012423 on ClinicalTrials.gov